drugset / Trial / NCT04258410
Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Double blind randomized controlled parallel pilot trial of Quercetin vs placebo oral administration in 24 postmenopausal women. The study team will conduct a feasibility pilot in preparation for a larger efficacy trial that will test the protective effects of quercetin against cardiac and skeletal muscle dysfunction and changes in structure induced by estrogen loss and potential mechanistic pathways in post-menopausal women at risk of heart failure with preserved ejection fraction (HFPEF).
Timeline
- Start
- 2022-09
- Primary completion
- 2023-12
- Completion
- 2024-01
Outcome
Outcome not reported
Stopped (Enrollment): “Per PI: "Never went to IRB Never recruited anyone Never resubmitted the score NIH application I am leaving the institution"”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quercetin | Small molecule | 500 mg | Oral |
Indications
No indication recorded.